Literature DB >> 19246367

Acute promyelocytic leukemia--weapons of mass differentiation.

Jonathan D Licht1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19246367     DOI: 10.1056/NEJMcibr0810371

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

1.  Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.

Authors:  Rihab Nasr; Hugues de Thé
Journal:  Int J Hematol       Date:  2010-05-11       Impact factor: 2.490

2.  PML-RARα induces all-trans retinoic acid-dependent transcriptional activation through interaction with MED1.

Authors:  Tomoya Fukuoka; Asami Kawai; Taku Takahara; Mahiro Mori; Robert G Roeder; Natsumi Hasegawa; Mitsuhiro Ito
Journal:  Transcription       Date:  2019-06-05

3.  FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Authors:  Cécile Esnault; Ramy Rahmé; Kim L Rice; Caroline Berthier; Coline Gaillard; Samuel Quentin; Anne-Lise Maubert; Scott Kogan; Hugues de Thé
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

4.  Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.

Authors:  Yiming Chen; Hagop Kantarjian; Haijun Wang; Jorge Cortes; Farhad Ravandi
Journal:  Cancer       Date:  2012-06-15       Impact factor: 6.860

Review 5.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.

Authors:  Hugues de Thé; Zhu Chen
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

6.  ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells.

Authors:  Aurore Trocoli; Julie Mathieu; Muriel Priault; Josy Reiffers; Sylvie Souquère; Gérard Pierron; Françoise Besançon; Mojgan Djavaheri-Mergny
Journal:  Autophagy       Date:  2011-10-01       Impact factor: 16.016

Review 7.  Curing all patients with acute promyelocytic leukemia: are we there yet?

Authors:  Muhamed Baljevic; Jae H Park; Eytan Stein; Dan Douer; Jessica K Altman; Martin S Tallman
Journal:  Hematol Oncol Clin North Am       Date:  2011-12       Impact factor: 3.722

8.  p62/SQSTM1 upregulation constitutes a survival mechanism that occurs during granulocytic differentiation of acute myeloid leukemia cells.

Authors:  A Trocoli; P Bensadoun; E Richard; G Labrunie; F Merhi; A M Schläfli; D Brigger; S Souquere; G Pierron; J-M Pasquet; P Soubeyran; J Reiffers; E Ségal-Bendirdjian; M P Tschan; M Djavaheri-Mergny
Journal:  Cell Death Differ       Date:  2014-07-18       Impact factor: 15.828

Review 9.  p53 as an Effector or Inhibitor of Therapy Response.

Authors:  Julien Ablain; Brigitte Poirot; Cécile Esnault; Jacqueline Lehmann-Che; Hugues de Thé
Journal:  Cold Spring Harb Perspect Med       Date:  2015-12-04       Impact factor: 6.915

10.  Interaction with RXR is necessary for NPM-RAR-induced myeloid differentiation blockade.

Authors:  Elizabeth A Rush; Sheri L Pollock; Irina Abecassis; Robert L Redner
Journal:  Leuk Res       Date:  2013-09-29       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.